Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779746 | 0.91 | MAN1B1 (0.35) | KDM1A | |
| SCHEMBL90396 | 0.86 | NCF1 (0.41) | KDM1AMAOBNCF1 | |
| SCHEMBL19780074 | 0.86 | HOGA1 (0.35) | KDM1A | |
| SCHEMBL19782072 | 0.80 | — | — | |
| SCHEMBL2616311 | 0.79 | NCF1 (0.48) | KDM1AMAOBNCF1 | |
| SCHEMBL25105479 | 0.79 | NCF1 (0.39) | KDM1AMAOBNCF1 | |
| SCHEMBL19781520 | 0.78 | SSTR2 (0.31) | — | |
| SCHEMBL19098593 | 0.78 | NCF1 (0.35) | KDM1AMAOBNCF1 | |
| SCHEMBL20206453 | 0.77 | EPHX2 (0.30) | — | |
| SCHEMBL30737475 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840531-B2 | CDK8/19 inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2023-12-12 | — | — | US | disclosed |
| US-20210246138-A1 | CDK8/19 INHIBITORS | JOINT STOCK COMPANY "BIOCAD" (RU) | 2021-08-12 | — | — | US | disclosed |
| EP-3831829-A1 | CDK8/19 INHIBITORS | Joint Stock Company "Biocad" (RU) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020027704-A1 | CDK8/19 INHIBITORS | ЗАКРЫТОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО "БИОКАД" | 2020-02-06 | — | — | WO | disclosed |
| WO-2018013676-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840531-B2 | CDK8/19 inhibitors | CDK8, CDK9, CDK18 | KDM1A 219/4885MAOB 3437/4885NCF1 1961/4885 |
| US-20210246138-A1 | CDK8/19 INHIBITORS | CDK8, CDK9, CDK18 | KDM1A 219/4885MAOB 3437/4885NCF1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.